To examine the prognostic survival values of mutational co-occurrence between mutations of ARID1A, EPHA2, PIK3CA and LAMA1 in CCA, we further performed survival analysis in CCA tumors with or without mutations of ARID1A, EPHA2, PIK3CA and LAMA1 (Table S1). The gene discussed is EPHA2; the disease is cholangiocarcinoma.